```html

Xerosis of the Vagina

Overview

Xerosis of the vagina (also called vaginal atrophy, vaginal dryness, or genitourinary syndrome of menopause when it occurs in post‑menopausal women) refers to thinning, loss of elasticity, and reduced lubrication of the vaginal epithelium. The condition results from a decrease in estrogen‑driven blood flow and secretions, leading to a dry, itchy, or painful vaginal environment.

Although it can affect women at any age, xerosis is most common after menopause. According to the North American Menopause Society, up to 50 % of post‑menopausal women report some degree of vaginal dryness, and about 30 % consider it severe enough to interfere with sexual activity.

Other groups at risk include:

• Women who have had oophorectomy or radiation therapy that lowers estrogen levels.
• Those using certain antihistamines, antidepressants, or hormonal contraceptives that reduce estrogen.
• Women with autoimmune diseases (e.g., Sjögren’s syndrome) that cause mucosal dryness.

Symptoms

Symptoms may be mild and intermittent or chronic and bothersome. Common complaints include:

Local Vaginal Symptoms

• Dryness – a sensation of “sandpaper” or rawness inside the vagina.
• Itching (pruritus) – often worse after sexual activity or intercourse.
• Burning or stinging – may be triggered by urine, sweat, or contact with soaps.
• Vaginal soreness – especially during or after intercourse (dyspareunia).
• Decreased vaginal lubrication – leading to discomfort during penetration.
• Feeling of tightness or pulling – due to thinning of the epithelium.
• Spotting or light bleeding – from fragile, atrophic tissue.

Secondary Symptoms

• Urinary symptoms – urgency, frequency, or recurrent urinary tract infections (UTIs) because the urethra shares the same estrogen‑dependent mucosa.
• Decreased sexual satisfaction – emotional distress, reduced desire, or avoidance of intimacy.
• Psychological impact – anxiety or depression stemming from chronic discomfort.

Causes and Risk Factors

Vaginal xerosis is fundamentally a problem of estrogen deficiency, but several direct and indirect factors can contribute.

Hormonal Changes

• Menopause – natural decline of ovarian estrogen production.
• Surgical menopause – removal of both ovaries (bilateral oophorectomy).
• Early menopause – induced by chemotherapy or radiation.

Medications

• Antihistamines and decongestants (e.g., diphenhydramine, pseudoephedrine)
• Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs)
• Anticholinergics used for overactive bladder
• Systemic glucocorticoids (long‑term use)

Medical Conditions

• Sjögren’s syndrome – autoimmune attack on exocrine glands.
• Diabetes – can affect microcirculation and mucosal health.
• Autoimmune thyroid disease.
• Chronic stress – may disturb hypothalamic‑pituitary‑ovarian axis.

Lifestyle and Environmental Factors

• Smoking – vasoconstriction reduces blood flow to vaginal tissues.
• Excessive alcohol consumption.
• Frequent use of scented hygiene products or douches that irritate the mucosa.
• Rough sexual activity without adequate lubrication.

Diagnosis

Diagnosis is primarily clinical, based on history and a focused pelvic examination.

Medical History

• Onset, duration, and severity of symptoms.
• Menstrual and reproductive history, including menopause age or surgical status.
• Medication list and recent changes.
• Sexual activity and use of lubricants or condoms.
• History of urinary infections, dermatologic conditions, or autoimmune disease.

Physical Examination

• Visual inspection of the vulva and vaginal walls for pallor, thinning, loss of rugae, or friability.
• Speculum exam to assess mucosal atrophy and pH (typically >4.5 in atrophic vaginitis).
• Gentle palpation to evaluate tissue elasticity.

Laboratory/Diagnostic Tests (when indicated)

• Vaginal pH testing – a basic strip; an elevated pH suggests atrophic changes.
• Wet mount microscopy – rules out infection (e.g., bacterial vaginosis, yeast).
• Hormone levels – serum estradiol, FSH, or LH may be checked in atypical cases.
• Biopsy – rarely needed, only if neoplasia is suspected.

Guidelines from the American College of Obstetricians and Gynecologists (ACOG) emphasize that a thorough history and visual exam are sufficient for most women with classic symptoms (ACOG Practice Bulletin No. 141, 2020).

Treatment Options

Treatment aims to restore moisture, improve tissue health, and alleviate discomfort. Options range from simple lifestyle changes to prescription medications.

Non‑Prescription (Over‑the‑Counter) Options

• Water‑based lubricants – applied before sexual activity; avoid those with glycerin or parabens if prone to irritation.
• Silicone‑based lubricants – longer lasting, safe with condoms.
• Vaginal moisturizers – e.g., Replens, used 2–3 times weekly for sustained hydration.
• Gentle, fragrance‑free cleansers – to avoid disrupting the natural flora.

Prescription Hormonal Therapies

• Low‑dose vaginal estrogen creams, tablets, or rings (e.g., estradiol 0.01% cream, 10 µg tablet, or estradiol/E2 ring). They deliver local estrogen with minimal systemic absorption. Most guidelines recommend an initial 2‑week course, then 1‑2 times per week maintenance.<sup>1</sup>
• Systemic estrogen therapy (oral, transdermal, or injectable) – considered when women have additional menopausal symptoms (hot flashes, bone loss). Requires evaluation of cardiovascular and thromboembolic risk.
• Selective estrogen receptor modulators (SERMs) – ospemifene 60 mg daily is FDA‑approved for dyspareunia due to vulvovaginal atrophy.

Non‑Hormonal Prescription Options

• Prasterone (DHEA) vaginal insert – 6.5 mg placed nightly; converts locally to estrogen and testosterone.
• Topical calcineurin inhibitors (e.g., tacrolimus ointment) – used off‑label for refractory inflammation, though data are limited.

Procedural Interventions

• Laser or radiofrequency vaginal rejuvenation – devices (e.g., CO₂ laser) stimulate collagen remodeling; evidence is emerging and not yet fully endorsed by professional societies.
• Platelet‑rich plasma (PRP) therapy – investigational, limited to clinical trials.

Adjunctive Therapies

• Pelvic floor physical therapy – improves muscle tone and blood flow.
• Stress‑reduction techniques (yoga, mindfulness) – may modulate hormonal balance.

Living with Xerosis of the Vagina

Even with treatment, day‑to‑day management can improve comfort and quality of life.

Daily Hygiene

• Wash with warm water only; avoid soaps, douches, or scented wipes.
• Pat dry gently; excess moisture can promote irritation.
• Wear breathable, cotton underwear; avoid tight synthetic garments.

Sexual Activity

• Use a high‑quality water‑ or silicone‑based lubricant before intercourse.
• Engage in extended foreplay to allow natural lubrication.
• Communicate openly with partners about comfort levels.

Lifestyle Adjustments

• Quit smoking – improves microcirculation.
• Stay hydrated (aim for 8 cups of water daily) to support mucosal moisture.
• Maintain a balanced diet rich in omega‑3 fatty acids, phytoestrogens (soy, flaxseed), and vitamin E, which may support tissue health.
• Regular moderate exercise (e.g., walking, swimming) enhances pelvic blood flow.

Follow‑Up Care

• Schedule a follow‑up visit 4‑6 weeks after starting any prescription therapy to assess response and adjust dosage.
• Annual pelvic exams are essential to screen for infections, cervical neoplasia, and other changes.

Prevention

While age‑related estrogen decline is inevitable, steps can be taken to delay or lessen severity.

• Early hormone evaluation – discuss menopausal symptoms with a healthcare provider before the onset of severe dryness.
• Regular use of moisturizers – starting in the perimenopausal years can maintain baseline hydration.
• Avoid irritants – fragrance‑free products and gentle cleansing.
• Healthy weight management – obesity can exacerbate systemic inflammation and hormone imbalance.
• Vaccination against HPV – reduces risk of cervical disease that could complicate the vaginal environment.

Complications

If left untreated, xerosis can lead to several downstream problems:

• Dyspareunia – chronic pain can strain relationships and cause emotional distress.
• Recurrent urinary tract infections – due to atrophic urethral mucosa.
• Vaginal bleeding or ulceration – fragile tissue may bleed with minor trauma.
• Increased risk of vaginal or cervical infections – altered flora and reduced barrier function.
• Pelvic floor muscle dysfunction – chronic discomfort may lead to muscle guarding and pelvic pain syndromes.

When to Seek Emergency Care

---

References:

1. North American Menopause Society. Hormone Therapy Position Statement. 2022.
2. American College of Obstetricians and Gynecologists. Practice Bulletin No. 141: Management of Menopausal Symptoms. 2020.
3. Mayo Clinic. Vaginal Atrophy. Accessed May 2024.
4. National Institutes of Health. Vaginal Dryness. 2023.
5. World Health Organization. Menopause. Updated 2023.

```